PRXL2AP1

Across TCGA pan-cancer cohorts, PRXL2AP1 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of PRXL2AP1’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where PRXL2AP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRXL2AP1 is over-expressed in tumor.

PRAD, HNSC, and LUSC are the cancer types where PRXL2AP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRXL2AP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.068	.016	2	view →
HNSC	Male	II,III,IV	+0.019	.046	2	view →
LUSC	Male	All	+0.012	.043	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

PRXL2AP1–PRAD

Open the PRAD breakdown →